Merck (MRK) Research & Development (2009 - 2026)

Merck (MRK) has reported Research & Development for 18 consecutive years, with $9.7 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Research & Development rose 140.64% year-over-year to $9.7 billion in Q2 2026; TTM through Jun 2026 was $26.7 billion, a 47.49% increase from a year earlier, with the FY2025 full-year figure at $15.8 billion, down 11.98% from the prior year.
• Research & Development was $9.7 billion for Q2 2026 at Merck, down from $12.6 billion in the prior quarter.
• Over five years, Research & Development peaked at $13.3 billion in Q2 2023 and troughed at $150.0 million in Q4 2025.
• A 5-year average of $5.1 billion and a median of $4.1 billion in 2025 frame the typical range for Research & Development.
• Across the five-year window, Research & Development soared 376.09% in 2023 and sank 96.73% in 2025, its largest moves.
• Over 5 years, Research & Development stood at $3.8 billion in 2022, then surged by 45.7% to $5.5 billion in 2023, then declined by 16.65% to $4.6 billion in 2024, then slumped by 96.73% to $150.0 million in 2025, then surged by 6394.0% to $9.7 billion in 2026.
• The last three Research & Development figures came in at $9.7 billion (Q2 2026), $12.6 billion (Q1 2026), and $150.0 million (Q4 2025), per Business Quant data.